1. Home
  2. ATOS vs TISI Comparison

ATOS vs TISI Comparison

Compare ATOS & TISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • TISI
  • Stock Information
  • Founded
  • ATOS 2009
  • TISI 1973
  • Country
  • ATOS United States
  • TISI United States
  • Employees
  • ATOS N/A
  • TISI N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • TISI Other Consumer Services
  • Sector
  • ATOS Health Care
  • TISI Consumer Discretionary
  • Exchange
  • ATOS Nasdaq
  • TISI Nasdaq
  • Market Cap
  • ATOS 112.5M
  • TISI 92.9M
  • IPO Year
  • ATOS 2012
  • TISI N/A
  • Fundamental
  • Price
  • ATOS $0.86
  • TISI $19.76
  • Analyst Decision
  • ATOS Strong Buy
  • TISI
  • Analyst Count
  • ATOS 4
  • TISI 0
  • Target Price
  • ATOS $6.17
  • TISI N/A
  • AVG Volume (30 Days)
  • ATOS 668.8K
  • TISI 17.6K
  • Earning Date
  • ATOS 05-13-2025
  • TISI 08-07-2025
  • Dividend Yield
  • ATOS N/A
  • TISI N/A
  • EPS Growth
  • ATOS N/A
  • TISI N/A
  • EPS
  • ATOS N/A
  • TISI N/A
  • Revenue
  • ATOS N/A
  • TISI $851,327,000.00
  • Revenue This Year
  • ATOS N/A
  • TISI N/A
  • Revenue Next Year
  • ATOS N/A
  • TISI N/A
  • P/E Ratio
  • ATOS N/A
  • TISI N/A
  • Revenue Growth
  • ATOS N/A
  • TISI N/A
  • 52 Week Low
  • ATOS $0.55
  • TISI $7.56
  • 52 Week High
  • ATOS $1.66
  • TISI $26.77
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 51.39
  • TISI 50.93
  • Support Level
  • ATOS $0.84
  • TISI $18.13
  • Resistance Level
  • ATOS $0.93
  • TISI $20.75
  • Average True Range (ATR)
  • ATOS 0.06
  • TISI 1.29
  • MACD
  • ATOS -0.00
  • TISI 0.05
  • Stochastic Oscillator
  • ATOS 66.40
  • TISI 59.35

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

Share on Social Networks: